FDA Pushing Generic Biologics Timetable In Election Year; "Structure" Expected Soon

Acting Commissioner Crawford's remarks on the feasibility of generic biologics reflect FDA's growing confidence that it can develop an approval pathway, after years of considering the issue too complex. He will testify on the issue during a Senate subcommittee hearing April 1.